Bayer HealthCare, LLC – FDA 483, Nov 13, 2019
An FDA inspection of Bayer Healthcare LLC in Berkeley, CA, identified critical deficiencies in quality control and manufacturing processes. These issues included the mislabeling of drug products, leading to a recall and adverse events, as well as inadequate investigation of discrepancies and failures in product testing for foreign materials. The findings highlight a need for improved procedural controls, robust testing methods, and effective document management to ensure product quality and patient safety.
ID · 099cd172-5e0d-4281-8a42-0607754a1152
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.